BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TNG456 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TNG456\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06810544-2771@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TNG456: Phase 1/2 readout est. (NCT06810544)
DESCRIPTION:TNG456\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Tolerability of TNG456 Alone and in Combination With Abemaciclib in P
 atients With Solid Tumors With MTAP Loss\nEstimated primary completion: 31
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tng456#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06810
 544
URL:https://assetmemo.bio/drug/tng456#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
